Shah Capital has ended its attempts to exert influence over vaccine developer Novavax, bringing more than years of activism ...

Swiss biotech Nouscom has closed a €120 million ($135 million) fourth-round financing for a vaccine to protect people with a ...

The immunology alliance follows a collaboration between the UK Biobank and the University of Exeter, supported by the Novo ...

On paper, the programme was built. In practice, many never crossed the finish line. Demand was not the problem. In a June ...

Pharmaceutical supply chains have more data at their fingertips than ever before. The challenge is turning that information into foresight. From temperature monitoring devices and connected containers ...

According to an update on the clinicaltrials.gov registry website, Novartis has terminated the study of Fabhalta (iptacopan) ...

The EMA's human medicines committee, the CHMP, has recommended approval of Eli Lilly's oral GLP-1 agonist Foundayo for weight ...

August and September brought leadership changes across healthcare communications, consulting, investment, and industry ...

From patient engagement apps to clinical trial management platforms, development teams are increasingly turning to AI coding ...

City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference (RNAi) therapies headed by a ...

Asahi Kasei's $920 million takeover of German biotech Aicuris in April has paid off with FDA approval for the herpes simplex ...

MSD has been rocked by a court judgment ordering it to stop manufacturing and selling its subcutaneous formulation of cancer ...